前列腺特异性膜抗原的临床应用与研究进展  

Clinical Application and Research Progress of Prostate Specific Membrane Antigen

作　　者：张才田[1] 王雪松[1] 崔毓桂[1] 

机构地区：[1]南京医科大学第一附属医院生殖医学中心,210029

出　　处：《国际生殖健康／计划生育杂志》2009年第3期201-204,共4页Journal of International Reproductive Health/Family Planning

摘　　要：前列腺特异性膜抗原(PSMA)是一种Ⅱ型跨膜糖蛋白,具有较高的组织特异性和膜结合性。在正常和恶性的前列腺上皮细胞以及多种非前列腺恶性实体肿瘤的新生毛细血管内皮细胞都有表达,而在前列腺外的其他正常组织表达极低,在前列腺癌,特别是非激素依赖型前列腺癌及其转移灶中表达增高。近年以其为靶向的诊断、治疗等临床应用研究进展迅速。Prostate Specific Membrane antigen （PSMA） is one of type Ⅱ transmembrane glycoproteins, with higher tissue specificity and membrane connectivity. There were PSMA expressions in the epithelial cells of normal and malignant prostate, as well as the endothelial cells of new capillaries in many malignant solid tumors originated from no-prostate tissue, while very low expression in the other normal tissues. The expression of PSMA was higher in prostatic cancer, especially the hormone-independent prostatic cancer and its metastasis. In recent years, studies on the clinical application of PSMA targeted diagnosis and treatment developed auickly.

关 键 词：前列腺特异性膜抗原 前列腺肿瘤 治疗 

分 类 号：R737.25[医药卫生—肿瘤] R446.5[医药卫生—临床医学]